DALLAS, Dec. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (USOTC: PURA) today announced that it expects demand for hemp-derived CBD infused beverages to skyrocket in reaction to the legalization of hemp farming that is part of the $867 billion Farm Bill passed yesterday by Congress and anticipated to be signed into law by President Trump soon. Puration has nearly two years of experience producing hemp-derived CBD infused beverages. Puration has a trailing twelve-month revenue of approximately $1 million and recently reported 400% year over year growth. The company has the sole license issued on a U.S. patented cannabis extraction process. Puration also has established its EVERx CBD Sports Water as a leading brand name in the CBD infused beverage market. EVERx was recently recognized for having attracted the attention of a major beverage industry player. Puration has recently been making weekly announcements of new regional distribution agreements and management anticipates similar announcements to continue through the end of the year.
“While most of the market consists of talk about CBD beverages one outfit or another plans to make, Puration has two years of actual go-to-market experience making and delivering CBD beverages,” said Brian Shibley, CEO of Puration. “Puration’s experience and brand recognition will set it far ahead of the Johnny-come-latelies trying to jump on the surge of demand for CBD beverages anticipated to be sparked by the legalization of hemp farming. Puration’s starting 2019 with a base of approximately $1 million in sales plus a brand new $1 million private label agreement. Come January 1st after President Trump signs the Farm Bill into law legalizing hemp farming, I expect PURA’s opportunities for CBD infused beverages to explode.”
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350